. 2017 Aug 9;6(9):2052–2062. doi: 10.1002/cam4.1143

Table 1.

Cox regression analysis HPV E6, PD‐L1 status, and combining E6 with PD‐L1 status on OS and RFS in NSCLC patients

	Patient No.	OS					Patient No.	RFS
	Patient No.	Median survival (month)	5‐year survival (%)	HR^a	95%CI	P	Patient No.	Median months	5‐ year survival (%)	HR^a	95%CI	P
E6 protein
Negative	71	27.4	23.0	1			68	24.4	7.1	1
Positive	51	21.5	12.3	1.49	0.95–2.32	0.080	46	19.0	13.4	1.28	0.80–2.03	0.302
PD‐L1
Negative	54	32.1	27.3	1			51	27.4	13.3	1
Positive	68	20.2	10.0	1.69	1.06–2.67	0.026	63	18.3	8.6	1.55	1.07–2.48	0.045
PD‐L1/HPV E6
Negative/Negative	37	34.1	31.8	1			35	31.6	10.2	1
Negative/Positive	17	21.5	17.6	1.89	0.84–3.81	0.076	16	21.5	16.7	1.45	0.71–2.99	0.312
Positive/Negative	34	20.3	16.1	2.00	1.08–3.71	0.027	33	18.3	11.2	1.71	0.93–3.15	0.086
Positive/Positive	34	19.0	6.4	2.30	1.23–4.30	0.009	30	18.3	5.7	1.90	0.99–3.65	0.053

The E6 immunostaining results were obtained from our previous reports 11, 12, 13, 14, and the detail procedure for the immunohistochemistry analysis was described previously.

Adjusted for stage.